Insulin Market Size, Share & Trends Analysis Report By Product (Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar), By Application, By Type, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Insulin Market Size, Share & Trends Analysis Report By Product (Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar), By Application, By Type, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Insulin Market Growth & Trends

The global insulin market size is estimated to reach USD 23.21 billion by 2030, registering to grow at a CAGR of 3.7% from 2025 to 2030 according to a new report by Grand View Research, Inc. It is an oligopolistic space dominated by companies such as Novo Nordisk A/S, Sanofi, and Eli Lilly and Company. The increasing incidence of diabetes and formulation advancements in insulin delivery are the primary factors driving growth. However, the presence of biosimilars and drugs such as GLP-1 RAs for the treatment of type 2 diabetes can slow down market growth to a certain extent.

Diabetes is one of the fastest-growing chronic diseases in the world. Its prevalence has increased steadily over the past few decades. The prevalence of the disease is growing rapidly in low- and middle-income countries; three in four adults live with diabetes in these countries. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. In addition, the increase in geriatric and obese populations is another factor driving growth. The overweight population is at risk of developing type 2 diabetes mellitus. According to WHO, in 2020, 1.9 billion adults were found to be overweight, accounting for 39% of the population within that age group.

Formulation advancements in insulin delivery systems are being developed, the release of which is likely to propel the market over the forecast period. In December 2019, Tandem Diabetes Care’s Control-IQ, an interoperable device, received FDA authorization for marketing in the U.S. It is an automated insulin dosing algorithm that can be used with other interoperable devices.

The top three manufacturing companies, Eli Lilly and Company, Novo Nordisk A/S, and Sanofi, hold a monopoly. These companies hold more than 90% of the market share. Owing to the oligopolistic nature of the market and patent protection, the cost of insulin is high. Hence, the high cost of products could impede industry growth.

The COVID-19 pandemic caused a detrimental impact on the industry. Individuals with chronic illnesses, such as diabetes, have experienced substantial disruptions in emergency and routine medical care. According to an NCBI article, out of ~30 million diabetic patients in America, about 7.5 million are dependent on insulin. Insulin rationing or hoarding has already been a rampant issue, which increased further amid the pandemic due to supply concerns. However, in several countries, the effect of COVID-19 declined to post the third quarter of 2020, which helped the market regain traction.

Insulin Market Report Highlights

• The long-acting insulin segment dominated the market and accounted for the largest revenue share of 52.4% in 2024.
• The type 1 diabetes mellitus segment dominated the market and accounted for the largest revenue share of 78.8% in 2024, driven by the rising incidence of this autoimmune condition among children and adults.
• The analog insulin segment dominated the market and accounted for the largest revenue share of 87.3% in 2024 due to its advantages over human insulin.
• The retail pharmacy segment dominated the market and accounted for the largest revenue share of 90.0% in 2024.

Please note The report will be delivered in 2-3 business days upon order notification.